利吉拉克托巴西勒斯 (Ligilactobacillus salivarius) V4II-90在怀孕期间消除了B组链球菌的殖民:一个随机,双盲,安慰剂对照的随机试验
A Gálvez1, E Dı Az de Terán2, J Á Espinosa3
1Department of Obstetrics and Gynecology, 207209Sanitas La Moraleja University Hospital, Madrid, Spain.
Beneficial microbes
|July 2, 2024
概括
在孕妇中,Ligilactobacillus salivarius V4II-90显著降低了B组链球菌 (GBS) 的殖民性. 这种益生菌干预提供了一种安全的策略,可以降低GBS的发病率和分娩期间的抗生素使用.
科学领域:
- 微生物学 微生物学
- 产科 产科 产科 产科 产科
- 新生儿健康 新生儿健康
背景情况:
- 乙组链球菌 (GBS) 是细菌新生儿败血症的主要原因.
- 需要有效的策略来减少怀孕期间的GBS殖民.
研究的目的:
- 评估Ligilactobacillus salivarius V4II-90在减少孕妇GBS殖民化的有效性.
- 评估这种益生菌干预对怀孕结果的安全性和影响.
主要方法:
- 这是一项随机,双盲,安慰剂对照试验,涉及44名患有GBS定居的孕妇.
- 参与者接受了L. salivarius V4II-90 (1x10^9 cfu/day) 或安慰剂12周,从怀孕21-23周开始.
- 主要结局:妊娠35周的GBS殖民率;次要结局包括不良事件和新生儿败血症.
主要成果:
- 在益生菌组的63%的参与者实现了GBS根除,而安慰剂组的27% (P=0.030).
- 没有任何不良事件归因于正在研究的产品.
- 干预表明,GBS殖民率显著下降.
结论:
- 口服L. salivarius V4II-90是一种安全有效的方法,可以减少怀孕后期的GBS殖民.
- 这种益生菌方法可能会降低对母亲和新生儿的产妇内抗生素预防的需要.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Probiotics
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
Development of Human Microbiota
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Development of the Oral Microbiota
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Streptococcal Pharyngitis
Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...


